Market Trends of Progesterone Industry
The Natural Progesterone Segment is Believed to Witness Healthy Growth Over the Forecast Period
The product segment includes natural progesterone and synthetic progesterone. Natural progesterone-based products include a combination of drug therapies made from soybeans or a wild, inedible Mexican yam called Dioscorea Villosa.
Natural progesterone is expected to witness lucrative growth during the forecast period as it has been studied to generate the largest number of prescriptions. Drugs, such as Crinone and Prometrium, are the major contributors to the revenue of the studied segment.
The major factors expected to drive the segment's growth are growing incidences of diseases such as abnormal uterine bleeding, breast or uterine cancer, other health complications, and a rising preference for natural progesterone. As per Cancer Australia, in 2021, it was estimated that 20,030 new breast cancer cases were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males).
According to an IARC estimate, in Europe, there were 530,666 breast cancer cases in 2020 and the number was estimated to increase to 569,320 by 2040.
Additionally, the rising product launches of natural progesterone are also expected to drive the growth of the studied segment. For instance, in November 2021, Fuji Pharma Co., Ltd launched the F-meno capsule 100 mg, a natural progesterone drug, in Japan. It is for the prevention of endometrial hyperplasia that can occur upon administration of estrogen drugs meant for menopausal disorders and ovarian deficiency. The high growth potential attained is a consequence of positive patient outcomes associated with natural progesterone. The positive patient outcomes can be attributed to significant improvements in hormonal interactions.
North America is Expected to Dominate the Progesterone Market Over the Forecast Period
North America is expected to hold a significant share, owing to the increasing adaptability of advanced treatments among the population. Also, increasing market players' strategies, such as collaborative efforts undertaken to enhance their R&D capabilities to meet the growing demand for progesterone, is expected to drive the growth of the market in this region. Moreover, the majority share can also be attributed to the high disease burden in this region. Increasing cases of kidney, breast, or uterine cancer types and the rising population of menopausal women in the region.
The rise in uterine body cancers in North America is also expected to contribute to the growth of the studied market in this region. In 2020, the American Cancer Society data estimated that in 2022, there would be 65,950 new cases of uterine body cancer in the United States.
Furthermore, around 10% of uterine body cancers are sarcoma. The market's growth can be attributed to factors such as the rising awareness of cancer diagnosis and the country's well-developed healthcare infrastructure. For instance, as per an October 2021 update by the Memorial Sloan Kettering Cancer Center, a new initiative was launched in May. This initiative aims to educate black women about endometrial cancer, help those diagnosed find appropriate care, and ultimately find treatments to improve outcomes for all women with the disease. Also, the Inside Knowledge campaign of the CDC in 2020, raises awareness of the five main types of gynecologic cancer: cervical, ovarian, uterine, vaginal, and vulvar.
Also, the increasing incidence of breast cancer in North America is expected to drive the demand for progesterone, thereby boosting the market's growth during the forecast period. Data published by the IARC in 2020 mentioned that the total number of breast cancer cases in 2020 was 281,491 and was expected to reach 343,426 by 2040.
Moreover, the rising market player activities such as product launches in the North American region are expected to contribute to the growth of the market. For instance, in May 2022, Xiromed LLC launched the Progesterone Injection USP, 500 mg/10 ml multiple-dose vial, generic progesterone to progesterone injection USP, 50 mg/ml.
